EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment March 7, 2023 FDA Approves Pembrolizumab with Chemotherapy for HER2-negative Gastric or Gastro-Oesophageal Junction... December 14, 2023 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... July 15, 2021 Load more HOT NEWS EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... Breast Cancer Patient Raising Money for 55 Women to Get Mammograms... Study Improves the Quality of Biopsy Specimens for Cancer Research Elections 2021: What the results mean for people with cancer
